EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC 4.0

Molecular assessment of intratumoral immune cell subsets and potential mechanisms of resistance to odronextamab, a CD20×CD3 bispecific antibody, in patients with relapsed/refractory B-cell non-Hodgkin lymphoma

Jurriaan Brouwer-Visser iD, Nathalie Fiaschi, Raquel P Deering, Kamil J Cygan, Darius Scott, Se Jeong, Lauren Boucher, Namita T Gupta, Suraj Gupta, Christina Adler, Max S Topp, Rajat Bannerji und 7 weitere

Journal for ImmunoTherapy of Cancer · 2024

DOI: 10.1136/jitc-2023-008338 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal for ImmunoTherapy of Cancer, 2024. Verfasst von Jurriaan Brouwer-Visser und 18 weiteren Autor:innen. Beteiligte Einrichtung: Regeneron Pharmaceuticals, Inc, Tarrytown, New York, USA jurriaan.brouwer@regeneron.com. Hauptthemen laut MEDLINE: Antineoplastic Agents, Lymphoma, Large B-Cell, Diffuse, Antibodies, Bispecific. Die Arbeit wurde bisher 28-mal zitiert (Crossref) und nennt 37 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Regeneron Pharmaceuticals.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Patients with relapsed/refractory B-cell non-Hodgkin lymphoma (R/R B-NHL) have a significant need for effective treatment options. Odronextamab is an Fc-silenced, human, CD20×CD3 bispecific antibody that targets CD20-expressing cells via T-cell-mediated cytotoxicity independent of T-cell/major histocompatibility complex interaction. Phase I results in patients with R/R B-NHL demonstrated that odronextamab monotherapy could achieve deep and durable responses with a generally manageable safety profile (ELM-1; NCT02290951 ). As part of a biomarker analysis of the same study, we investigated potential biomarkers and mechanisms of resistance to odronextamab.

Methods

Patients with R/R B-NHL enrolled in ELM-1 received one time per week doses of intravenous odronextamab for 4×21 day cycles, then doses every 2 weeks thereafter. Patient tumor biopsies were obtained at baseline, on-treatment, and at progression. Immune cell markers were analyzed by immunohistochemistry, flow cytometry, single-cell RNA sequencing, and whole genome sequencing.

Results

Baseline tumor biopsies showed that almost all patients had high proportions of B cells that expressed the CD20 target antigen, whereas expression of other B-cell surface antigens (CD19, CD22, CD79b) was more variable. Responses to odronextamab in patients with diffuse large B-cell lymphoma were not related to the relative level of baseline CD20 expression, cell of origin, or high-risk molecular subtype. A potential link was observed between greater tumor programmed cell death-ligand 1 expression and increased likelihood of response to odronextamab. Similarly, a trend was observed between clinical response and increased levels of CD8 T cells and regulatory T cells at baseline. We also identified an on-treatment pharmacodynamic shift in intratumoral immune cell subsets. Finally, loss of CD20 expression through inactivating gene mutations was identified as a potential mechanism of resistance in patients who were treated with odronextamab until progression, as highlighted in two detailed patient cases reported here.

Conclusions

This biomarker analysis expands on clinical findings of odronextamab in patients with R/R B-NHL, providing verification of the suitability of CD20 as a therapeutic target, as well as evidence for potential mechanisms of action and resistance.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Antineoplastic AgentsLymphoma, Large B-Cell, DiffuseAntibodies, BispecificHumansTreatment OutcomeAntigens, CD20

Stichwörter der Autor:innen

Antibodies, BispecificBiomarkers, Tumor

Substanzen

Antineoplastic AgentsAntibodies, BispecificAntigens, CD20

Autor:innen und Institutionen

  • Regeneron Pharmaceuticals, Inc, Tarrytown, New York, USA jurriaan.brouwer@regeneron.com.
  • Regeneron Pharmaceuticals, Inc, Tarrytown, New York, USA.
  • Department of Internal Medicine II, University Hospital Würzburg, Würzburg, Germany.
  • Rutgers Cancer Institute of New Jersey, New Brunswick, New Jersey, USA.
  • Department of Medicine, Stanford University, Stanford, California, USA.

ORCID-Profile: Jurriaan Brouwer-Visser

Förderung

  • Regeneron Pharmaceuticals

Zitieren

APA

Brouwer-Visser, J., Fiaschi, N., Deering, R. P., Cygan, K. J., Scott, D., Jeong, S., Boucher, L., Gupta, N. T., Gupta, S., Adler, C., Topp, M. S., Bannerji, R., Duell, J., Advani, R. H., Flink, D. M., Chaudhry, A., Thurston, G., Ambati, S. R., & Jankovic, V. (2024). Molecular assessment of intratumoral immune cell subsets and potential mechanisms of resistance to odronextamab, a CD20×CD3 bispecific antibody, in patients with relapsed/refractory B-cell non-Hodgkin lymphoma. Journal for ImmunoTherapy of Cancer. https://doi.org/10.1136/jitc-2023-008338

Vancouver

Brouwer-Visser J, Fiaschi N, Deering RP, Cygan KJ, Scott D, Jeong S, et al. Molecular assessment of intratumoral immune cell subsets and potential mechanisms of resistance to odronextamab, a CD20×CD3 bispecific antibody, in patients with relapsed/refractory B-cell non-Hodgkin lymphoma. Journal for ImmunoTherapy of Cancer. 2024. doi:10.1136/jitc-2023-008338

BibTeX
@article{BrouwerVisser2024,
  author = {Brouwer-Visser, Jurriaan and Fiaschi, Nathalie and Deering, Raquel P and Cygan, Kamil J and Scott, Darius and Jeong, Se and Boucher, Lauren and Gupta, Namita T and Gupta, Suraj and Adler, Christina and Topp, Max S and Bannerji, Rajat and Duell, Johannes and Advani, Ranjana H and Flink, Dina M and Chaudhry, Aafia and Thurston, Gavin and Ambati, Srikanth R and Jankovic, Vladimir},
  title = {Molecular assessment of intratumoral immune cell subsets and potential mechanisms of resistance to odronextamab, a CD20×CD3 bispecific antibody, in patients with relapsed/refractory B-cell non-Hodgkin lymphoma},
  journal = {Journal for ImmunoTherapy of Cancer},
  year = {2024},
  doi = {10.1136/jitc-2023-008338}
}
Kostenlos starten →